← Back to Search

Nonsteroidal Anti-inflammatory Drug

Aspirin for Prophylaxis of Preeclampsia (APROACH-PK Trial)

Phase 1 & 2
Waitlist Available
Led By Rupsa C Boelig, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Singleton pregnancy
Plan to take 81mg aspirin due to high risk history (below), but not yet initiated
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hour
Awards & highlights

APROACH-PK Trial Summary

This trial will study how a pregnant woman's body processes and responds to medication during different stages of pregnancy.

Eligible Conditions
  • Prophylaxis of Preeclampsia

APROACH-PK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

APROACH-PK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PFA-100
salicylic acid level
serum thromboxane
Secondary outcome measures
Urinary thromboxane

APROACH-PK Trial Design

1Treatment groups
Experimental Treatment
Group I: AspirinExperimental Treatment1 Intervention
81mg aspirin daily

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
443 Previous Clinical Trials
145,480 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
1,953 Previous Clinical Trials
2,660,666 Total Patients Enrolled
March of DimesOTHER
22 Previous Clinical Trials
30,278 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025